Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Product Launch

Biocon Product Launch

Biocon Limited has commercially launched 'Yesafili', a biosimilar to Eylea, in the United States market. This product strengthens the company's ophthalmology portfolio.

Source

BSE filing, NSE: BIOCON. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Biocon Ltd: key numbers

Share price
₹350.70
Market cap
₹57,153 Cr
Revenue (annual)
₹16,927 Cr
Net profit (annual)
₹385.6 Cr
P/E (TTM)
115.4×Sector 46.1×
Promoter holding
44.68%+0.00% QoQ
FII holding
8.64%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Biocon Ltd

All →
08:25 IST BSE
Partnership

Biocon Partnership

Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.

From
Genentech

Other product launch announcements

All →